Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
19.61
+0.66 (3.48%)
At close: Oct 27, 2025, 4:00 PM EDT
19.62
+0.01 (0.05%)
After-hours: Oct 27, 2025, 7:51 PM EDT
Teva Pharmaceutical Revenue
Teva Pharmaceutical had revenue of $4.18B in the quarter ending June 30, 2025, with 0.29% growth. This brings the company's revenue in the last twelve months to $16.63B, up 2.07% year-over-year. In the year 2024, Teva Pharmaceutical had annual revenue of $16.54B with 4.40% growth.
Revenue (ttm)
$16.63B
Revenue Growth
+2.07%
P/S Ratio
1.34
Revenue / Employee
$451,480
Employees
36,830
Market Cap
22.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
| Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
| Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
| Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
| Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
TEVA News
- 7 days ago - Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe - GlobeNewsWire
- 10 days ago - Teva Vs. Viatris: Who Will Dominate In President Trump's America? - Seeking Alpha
- 17 days ago - FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder - GlobeNewsWire
- 20 days ago - Teva Pharmaceutical: Turnaround Driven By Huge Pipeline Upside - Seeking Alpha
- 4 weeks ago - Teva Releases Q3 2025 Aide Memoire - GlobeNewsWire
- 4 weeks ago - Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025 - GlobeNewsWire
- 4 weeks ago - Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors - Seeking Alpha
- 4 weeks ago - Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2025 Transcript - Seeking Alpha